APO Research
Talk to an analyst

APO RESEARCH · REPORT

Opioid Antagonist

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Opioid Antagonist Market Outlook and Growth Opportunities 2026

19 December 2025191 pages

Choose your research edition.

Industry ResearchOpioid Antagonist Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Opioid Antagonist Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Opioid Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Opioid Antagonist Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Opioid Antagonist Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Opioid Antagonist market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Opioid Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Opioid Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Opioid Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Opioid Antagonist market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Opioid Antagonist market include Titan Pharmaceuticals, AstraZeneca, Shionogi, Orexo, Opiant Pharmaceuticals, Indivior, Hikma Pharmaceuticals, Collegium Pharmaceutical and Camurus, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Opioid Antagonist market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Opioid Antagonist and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Opioid Antagonist sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Opioid Antagonist market size, projected growth trends, production technologies, key applications, and end-use industries.

Opioid Antagonist Segment by Company

Titan Pharmaceuticals

AstraZeneca

Shionogi

Orexo

Opiant Pharmaceuticals

Indivior

Hikma Pharmaceuticals

Collegium Pharmaceutical

Camurus

BioDelivery Sciences International

Alkermes

Acura Pharmaceuticals

Opioid Antagonist Segment by Type

Oral

Parenteral

Opioid Antagonist Segment by Application

Hospitals

Clinics

Others

Opioid Antagonist Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Opioid Antagonist status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Opioid Antagonist market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Opioid Antagonist significant trends, drivers, influence factors in global and regions.

6. To analyze Opioid Antagonist competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Opioid Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid Antagonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Opioid Antagonist market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Opioid Antagonist industry.

Chapter 3: Detailed analysis of Opioid Antagonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Opioid Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Opioid Antagonist in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Opioid Antagonist Industry Trends Table 2. Opioid Antagonist Industry Drivers Table 3. Opioid Antagonist Industry Opportunities and Challenges Table 4. Opioid Antagonist Industry Restraints Table 5. Global Opioid Antagonist Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Opioid Antagonist Revenue Share by Company (2021-2026) Table 7. Global Opioid Antagonist Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Opioid Antagonist Sales Volume Share by Company (2021-2026) Table 9. Global Opioid Antagonist Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Opioid Antagonist Company Ranking, (2024-2026) & (USD Million) Table 11. Global Opioid Antagonist Key Company Manufacturing Base & Headquarters Table 12. Global Opioid Antagonist Company, Product Type & Application Table 13. Global Opioid Antagonist Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Opioid Antagonist by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oral Table 18. Significant Companies of Parenteral Table 19. Global Opioid Antagonist Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Opioid Antagonist Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Opioid Antagonist Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Opioid Antagonist Sales Volume Share by Type (2021-2026) Table 23. Global Opioid Antagonist Sales Volume Share by Type (2027-2032) Table 24. Global Opioid Antagonist Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Opioid Antagonist Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Opioid Antagonist Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Opioid Antagonist Sales Value Share by Type (2021-2026) Table 28. Global Opioid Antagonist Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospitals Table 30. Significant Companies of Clinics Table 31. Significant Companies of Others Table 32. Global Opioid Antagonist Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Opioid Antagonist Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Opioid Antagonist Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Opioid Antagonist Sales Volume Share by Application (2021-2026) Table 36. Global Opioid Antagonist Sales Volume Share by Application (2027-2032) Table 37. Global Opioid Antagonist Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Opioid Antagonist Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Opioid Antagonist Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Opioid Antagonist Sales Value Share by Application (2021-2026) Table 41. Global Opioid Antagonist Sales Value Share by Application (2027-2032) Table 42. Global Opioid Antagonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Opioid Antagonist Sales by Region (2021-2026) & (K Units) Table 44. Global Opioid Antagonist Sales Market Share by Region (2021-2026) Table 45. Global Opioid Antagonist Sales by Region (2027-2032) & (K Units) Table 46. Global Opioid Antagonist Sales Market Share by Region (2027-2032) Table 47. Global Opioid Antagonist Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Opioid Antagonist Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Opioid Antagonist Sales Value Share by Region (2021-2026) Table 50. Global Opioid Antagonist Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Opioid Antagonist Sales Value Share by Region (2027-2032) Table 52. Global Opioid Antagonist Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Opioid Antagonist Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Opioid Antagonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Opioid Antagonist Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Opioid Antagonist Sales by Country (2021-2026) & (K Units) Table 57. Global Opioid Antagonist Sales Market Share by Country (2021-2026) Table 58. Global Opioid Antagonist Sales by Country (2027-2032) & (K Units) Table 59. Global Opioid Antagonist Sales Market Share by Country (2027-2032) Table 60. Global Opioid Antagonist Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Opioid Antagonist Sales Value Market Share by Country (2021-2026) Table 62. Global Opioid Antagonist Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Opioid Antagonist Sales Value Market Share by Country (2027-2032) Table 64. Titan Pharmaceuticals Company Information Table 65. Titan Pharmaceuticals Business Overview Table 66. Titan Pharmaceuticals Opioid Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Titan Pharmaceuticals Opioid Antagonist Product Portfolio Table 68. Titan Pharmaceuticals Recent Development Table 69. AstraZeneca Company Information Table 70. AstraZeneca Business Overview Table 71. AstraZeneca Opioid Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. AstraZeneca Opioid Antagonist Product Portfolio Table 73. AstraZeneca Recent Development Table 74. Shionogi Company Information Table 75. Shionogi Business Overview Table 76. Shionogi Opioid Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Shionogi Opioid Antagonist Product Portfolio Table 78. Shionogi Recent Development Table 79. Orexo Company Information Table 80. Orexo Business Overview Table 81. Orexo Opioid Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Orexo Opioid Antagonist Product Portfolio Table 83. Orexo Recent Development Table 84. Opiant Pharmaceuticals Company Information Table 85. Opiant Pharmaceuticals Business Overview Table 86. Opiant Pharmaceuticals Opioid Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Opiant Pharmaceuticals Opioid Antagonist Product Portfolio Table 88. Opiant Pharmaceuticals Recent Development Table 89. Indivior Company Information Table 90. Indivior Business Overview Table 91. Indivior Opioid Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Indivior Opioid Antagonist Product Portfolio Table 93. Indivior Recent Development Table 94. Hikma Pharmaceuticals Company Information Table 95. Hikma Pharmaceuticals Business Overview Table 96. Hikma Pharmaceuticals Opioid Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Hikma Pharmaceuticals Opioid Antagonist Product Portfolio Table 98. Hikma Pharmaceuticals Recent Development Table 99. Collegium Pharmaceutical Company Information Table 100. Collegium Pharmaceutical Business Overview Table 101. Collegium Pharmaceutical Opioid Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Collegium Pharmaceutical Opioid Antagonist Product Portfolio Table 103. Collegium Pharmaceutical Recent Development Table 104. Camurus Company Information Table 105. Camurus Business Overview Table 106. Camurus Opioid Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Camurus Opioid Antagonist Product Portfolio Table 108. Camurus Recent Development Table 109. BioDelivery Sciences International Company Information Table 110. BioDelivery Sciences International Business Overview Table 111. BioDelivery Sciences International Opioid Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. BioDelivery Sciences International Opioid Antagonist Product Portfolio Table 113. BioDelivery Sciences International Recent Development Table 114. Alkermes Company Information Table 115. Alkermes Business Overview Table 116. Alkermes Opioid Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Alkermes Opioid Antagonist Product Portfolio Table 118. Alkermes Recent Development Table 119. Acura Pharmaceuticals Company Information Table 120. Acura Pharmaceuticals Business Overview Table 121. Acura Pharmaceuticals Opioid Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Acura Pharmaceuticals Opioid Antagonist Product Portfolio Table 123. Acura Pharmaceuticals Recent Development Table 124. Key Raw Materials Table 125. Raw Materials Key Suppliers Table 126. Opioid Antagonist Distributors List Table 127. Opioid Antagonist Customers List Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Opioid Antagonist Product Image Figure 2. Global Opioid Antagonist Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Opioid Antagonist Sales Value (2021-2032) & (US$ Million) Figure 4. Global Opioid Antagonist Sales (2021-2032) & (K Units) Figure 5. Global Opioid Antagonist Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Opioid Antagonist Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oral Image Figure 10. Parenteral Image Figure 11. Global Opioid Antagonist Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Opioid Antagonist Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Opioid Antagonist Sales Volume Share by Type (2021-2032) Figure 14. Global Opioid Antagonist Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Opioid Antagonist Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Opioid Antagonist Sales Value Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Clinics Image Figure 19. Others Image Figure 20. Global Opioid Antagonist Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Opioid Antagonist Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Opioid Antagonist Sales Volume Share by Application (2021-2032) Figure 23. Global Opioid Antagonist Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Opioid Antagonist Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Opioid Antagonist Sales Value Share by Application (2021-2032) Figure 26. Global Opioid Antagonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Opioid Antagonist Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Opioid Antagonist Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Opioid Antagonist Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Opioid Antagonist Sales Value (2021-2032) & (US$ Million) Figure 31. North America Opioid Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Opioid Antagonist Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Opioid Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Opioid Antagonist Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Opioid Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Opioid Antagonist Sales Value (2021-2032) & (US$ Million) Figure 37. South America Opioid Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Opioid Antagonist Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Opioid Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Opioid Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Opioid Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Opioid Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Opioid Antagonist Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Opioid Antagonist Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Parenteral
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Titan Pharmaceuticals
  • AstraZeneca
  • Shionogi
  • Orexo
  • Opiant Pharmaceuticals
  • Indivior
  • Hikma Pharmaceuticals
  • Collegium Pharmaceutical
  • Camurus
  • BioDelivery Sciences International
  • Alkermes
  • Acura Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Opioid Antagonist Sales Value (2021-2032)
  4. 1.2.2 Global Opioid Antagonist Sales Volume (2021-2032)
  5. 1.2.3 Global Opioid Antagonist Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Opioid Antagonist Market Dynamics
  1. 2.1 Opioid Antagonist Industry Trends
  2. 2.2 Opioid Antagonist Industry Drivers
  3. 2.3 Opioid Antagonist Industry Opportunities and Challenges
  4. 2.4 Opioid Antagonist Industry Restraints
3 Opioid Antagonist Market by Company
  1. 3.1 Global Opioid Antagonist Company Revenue Ranking in 2025
  2. 3.2 Global Opioid Antagonist Revenue by Company (2021-2026)
  3. 3.3 Global Opioid Antagonist Sales Volume by Company (2021-2026)
  4. 3.4 Global Opioid Antagonist Average Price by Company (2021-2026)
  5. 3.5 Global Opioid Antagonist Company Ranking (2024-2026)
  6. 3.6 Global Opioid Antagonist Company Manufacturing Base and Headquarters
  7. 3.7 Global Opioid Antagonist Company Product Type and Application
  8. 3.8 Global Opioid Antagonist Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Opioid Antagonist Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Opioid Antagonist Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Opioid Antagonist Market by Type
  1. 4.1 Opioid Antagonist Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Parenteral
  4. 4.2 Global Opioid Antagonist Sales Volume by Type
  5. 4.2.1 Global Opioid Antagonist Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Opioid Antagonist Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Opioid Antagonist Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Opioid Antagonist Sales Value by Type
  9. 4.3.1 Global Opioid Antagonist Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Opioid Antagonist Sales Value by Type (2021-2032)
  11. 4.3.3 Global Opioid Antagonist Sales Value Share by Type (2021-2032)
5 Opioid Antagonist Market by Application
  1. 5.1 Opioid Antagonist Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Opioid Antagonist Sales Volume by Application
  6. 5.2.1 Global Opioid Antagonist Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Opioid Antagonist Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Opioid Antagonist Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Opioid Antagonist Sales Value by Application
  10. 5.3.1 Global Opioid Antagonist Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Opioid Antagonist Sales Value by Application (2021-2032)
  12. 5.3.3 Global Opioid Antagonist Sales Value Share by Application (2021-2032)
6 Opioid Antagonist Regional Sales and Value Analysis
  1. 6.1 Global Opioid Antagonist Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Opioid Antagonist Sales by Region (2021-2032)
  3. 6.2.1 Global Opioid Antagonist Sales by Region: 2021-2026
  4. 6.2.2 Global Opioid Antagonist Sales by Region (2027-2032)
  5. 6.3 Global Opioid Antagonist Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Opioid Antagonist Sales Value by Region (2021-2032)
  7. 6.4.1 Global Opioid Antagonist Sales Value by Region: 2021-2026
  8. 6.4.2 Global Opioid Antagonist Sales Value by Region (2027-2032)
  9. 6.5 Global Opioid Antagonist Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Opioid Antagonist Sales Value (2021-2032)
  12. 6.6.2 North America Opioid Antagonist Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Opioid Antagonist Sales Value (2021-2032)
  15. 6.7.2 Europe Opioid Antagonist Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Opioid Antagonist Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Opioid Antagonist Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Opioid Antagonist Sales Value (2021-2032)
  21. 6.9.2 South America Opioid Antagonist Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Opioid Antagonist Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Opioid Antagonist Sales Value Share by Country, 2025 VS 2032
7 Opioid Antagonist Country-level Sales and Value Analysis
  1. 7.1 Global Opioid Antagonist Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Opioid Antagonist Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Opioid Antagonist Sales by Country (2021-2032)
  4. 7.3.1 Global Opioid Antagonist Sales by Country (2021-2026)
  5. 7.3.2 Global Opioid Antagonist Sales by Country (2027-2032)
  6. 7.4 Global Opioid Antagonist Sales Value by Country (2021-2032)
  7. 7.4.1 Global Opioid Antagonist Sales Value by Country (2021-2026)
  8. 7.4.2 Global Opioid Antagonist Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Opioid Antagonist Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Opioid Antagonist Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Opioid Antagonist Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Opioid Antagonist Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Opioid Antagonist Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Opioid Antagonist Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Opioid Antagonist Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Opioid Antagonist Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Opioid Antagonist Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Opioid Antagonist Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Opioid Antagonist Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Opioid Antagonist Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Opioid Antagonist Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Opioid Antagonist Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Opioid Antagonist Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Opioid Antagonist Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Opioid Antagonist Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Opioid Antagonist Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Opioid Antagonist Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Opioid Antagonist Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Opioid Antagonist Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Opioid Antagonist Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Opioid Antagonist Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Opioid Antagonist Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Opioid Antagonist Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Opioid Antagonist Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Opioid Antagonist Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Opioid Antagonist Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Opioid Antagonist Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Opioid Antagonist Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Titan Pharmaceuticals
  2. 8.1.1 Titan Pharmaceuticals Company Information
  3. 8.1.2 Titan Pharmaceuticals Business Overview
  4. 8.1.3 Titan Pharmaceuticals Opioid Antagonist Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Titan Pharmaceuticals Opioid Antagonist Product Portfolio
  6. 8.1.5 Titan Pharmaceuticals Recent Developments
  7. 8.2 AstraZeneca
  8. 8.2.1 AstraZeneca Company Information
  9. 8.2.2 AstraZeneca Business Overview
  10. 8.2.3 AstraZeneca Opioid Antagonist Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 AstraZeneca Opioid Antagonist Product Portfolio
  12. 8.2.5 AstraZeneca Recent Developments
  13. 8.3 Shionogi
  14. 8.3.1 Shionogi Company Information
  15. 8.3.2 Shionogi Business Overview
  16. 8.3.3 Shionogi Opioid Antagonist Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Shionogi Opioid Antagonist Product Portfolio
  18. 8.3.5 Shionogi Recent Developments
  19. 8.4 Orexo
  20. 8.4.1 Orexo Company Information
  21. 8.4.2 Orexo Business Overview
  22. 8.4.3 Orexo Opioid Antagonist Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Orexo Opioid Antagonist Product Portfolio
  24. 8.4.5 Orexo Recent Developments
  25. 8.5 Opiant Pharmaceuticals
  26. 8.5.1 Opiant Pharmaceuticals Company Information
  27. 8.5.2 Opiant Pharmaceuticals Business Overview
  28. 8.5.3 Opiant Pharmaceuticals Opioid Antagonist Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Opiant Pharmaceuticals Opioid Antagonist Product Portfolio
  30. 8.5.5 Opiant Pharmaceuticals Recent Developments
  31. 8.6 Indivior
  32. 8.6.1 Indivior Company Information
  33. 8.6.2 Indivior Business Overview
  34. 8.6.3 Indivior Opioid Antagonist Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Indivior Opioid Antagonist Product Portfolio
  36. 8.6.5 Indivior Recent Developments
  37. 8.7 Hikma Pharmaceuticals
  38. 8.7.1 Hikma Pharmaceuticals Company Information
  39. 8.7.2 Hikma Pharmaceuticals Business Overview
  40. 8.7.3 Hikma Pharmaceuticals Opioid Antagonist Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Hikma Pharmaceuticals Opioid Antagonist Product Portfolio
  42. 8.7.5 Hikma Pharmaceuticals Recent Developments
  43. 8.8 Collegium Pharmaceutical
  44. 8.8.1 Collegium Pharmaceutical Company Information
  45. 8.8.2 Collegium Pharmaceutical Business Overview
  46. 8.8.3 Collegium Pharmaceutical Opioid Antagonist Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Collegium Pharmaceutical Opioid Antagonist Product Portfolio
  48. 8.8.5 Collegium Pharmaceutical Recent Developments
  49. 8.9 Camurus
  50. 8.9.1 Camurus Company Information
  51. 8.9.2 Camurus Business Overview
  52. 8.9.3 Camurus Opioid Antagonist Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Camurus Opioid Antagonist Product Portfolio
  54. 8.9.5 Camurus Recent Developments
  55. 8.10 BioDelivery Sciences International
  56. 8.10.1 BioDelivery Sciences International Company Information
  57. 8.10.2 BioDelivery Sciences International Business Overview
  58. 8.10.3 BioDelivery Sciences International Opioid Antagonist Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 BioDelivery Sciences International Opioid Antagonist Product Portfolio
  60. 8.10.5 BioDelivery Sciences International Recent Developments
  61. 8.11 Alkermes
  62. 8.11.1 Alkermes Company Information
  63. 8.11.2 Alkermes Business Overview
  64. 8.11.3 Alkermes Opioid Antagonist Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Alkermes Opioid Antagonist Product Portfolio
  66. 8.11.5 Alkermes Recent Developments
  67. 8.12 Acura Pharmaceuticals
  68. 8.12.1 Acura Pharmaceuticals Company Information
  69. 8.12.2 Acura Pharmaceuticals Business Overview
  70. 8.12.3 Acura Pharmaceuticals Opioid Antagonist Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Acura Pharmaceuticals Opioid Antagonist Product Portfolio
  72. 8.12.5 Acura Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Opioid Antagonist Value Chain Analysis
  2. 9.1.1 Opioid Antagonist Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Opioid Antagonist Sales Mode & Process
  6. 9.2 Opioid Antagonist Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Opioid Antagonist Distributors
  9. 9.2.3 Opioid Antagonist Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst